News & Resources

The Cancer Immunotherapy Consortium (CIC) contributes to the creation of white papers, response documents, and peer-reviewed publications advancing novel outcomes from workshops that seek practical solutions to today's challenges in cancer immunotherapy development.

Publications

• Structured reporting of T cell assay results. Janetzki S, Hoos A, Melief CJM, Odunsi K, Romero P, Britten CM. Cancer Immunity 2013; 13: 13.
• A harmonized approach to intracellular cytokine staining gating: Results from an international multiconsortia proficiency panel conducted by the cancer immunotherapy consortium (CIC/CRI). McNeil LK, Price L, Britten CM, Jaimes M, Maecker H, Odunsi K, Matsuzaki J, Staats JS, Thorpe J, Yuan J, Janetzki S. Cytometry A 2013; Jun 20.
• The impact of harmonization on ELISPOT assay performance. Janetzki S, Britten CM. Methods Mol Biol 2012 ;792: 25-36.
• Advancing the field of cancer immunotherapy: MIATA consensus guidelines become available to improve data reporting and interpretation for T-cell immune monitoring. Hoos A, Janetzki S, Britten CM. Oncoimmunology 2012; 1: 1457-1459.
• T cell assays and MIATA: the essential minimum for maximum impact [PDF]. Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. Immunity 2012; 37: 1-2.
• The immuno-oncology framework: Enabling a new era of cancer therapy. Hoos A, Britten C. Oncoimmunology 2012; 1: 334-339.
• A critical assessment for the value of markers to gate-out undesired events in HLA-peptide multimer staining protocols. Attig S, Price L, Janetzki S, Kalos M, Pride M, McNeil L, Clay T, Yuan J, Odunsi K, Hoos A, Romero P, Britten CM; CRI-CIC Assay Working Group. J Transl Med 2011; 9: 108
• Harmonization of immune biomarker assays for clinical studies. van der Burg SH, Kalos M, Gouttefangeas C, Janetzki S, Ottensmeier C, Welters MJ, Romero P, Britten CM, Hoos A. Sci Transl Med 2011; 3: 108ps44.
• A methodological framework to enhance the clinical success of cancer immunotherapy. Hoos A, Britten CM, Huber C, O'Donnell-Tormey J. Nat Biotechnol 2011; 29: 867-870.
• Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond . Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Pawelec G, Roep BO, Romero P, Hoos A, Davis MM. Cancer Immunol Immunother 2011; 60: 15-22.
• Improved endpoints for cancer immunotherapy trials. Hoos A, Eggermont AM, Janetzki S, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. J Natl Cancer Inst 2010; 102:1388-97.
• Performance of serum-supplemented and serum-free media in IFNγ Elispot Assays for human T cells. Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A. Cancer Immunol Immunother 2010; 59: 609-18.
• Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Clin Cancer Res 2009; 15: 7412-20.
• "MIATA"-minimal information about T cell assays. Janetzki S, Britten CM, Kalos M, Levitsky HI, Maecker HT, Melief CJ, Old LJ, Romero P, Hoos A, Davis MM. Immunity 2009; 16; 31: 527-8.
• Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium. Britten CM, Janetzki S, Ben-Porat L, Clay TM, Kalos M, Maecker H, Odunsi K, Pride M, Old L, Hoos A, Romero P; HLA-peptide Multimer Proficiency Panel of the CVC-CRI Immune Assay Working Group. Cancer Immunol Immunother 2009; 58: 1701-13.
• Lessons from randomized phase III studies with active cancer immunotherapies--outcomes from the 2006 meeting of the Cancer Vaccine Consortium (CVC). Finke LH, Wentworth K, Blumenstein B, Rudolph NS, Levitsky H, Hoos A. Vaccine 2007; 25 Suppl 2: B97-B109. Review.
• Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI). Janetzki S, Panageas KS, Ben-Porat L, Boyer J, Britten CM, Clay TM, Kalos M, Maecker HT, Romero P, Yuan J, Kast WM, Hoos A; Elispot Proficiency Panel of the CVC Immune Assay Working Group. Cancer Immunol Immunother 2008; 57: 303-15.
• Toward the harmonization of immune monitoring in clinical trials: quo vadis? Britten CM, Janetzki S, van der Burg SH, Gouttefangeas C, Hoos A. Cancer Immunol Immunother 2008; 57: 285-8.
• A clinical development paradigm for cancer vaccines and related biologics. Hoos A, Parmiani G, Hege K, Sznol M, Loibner H, Eggermont A, Urba W, Blumenstein B, Sacks N, Keilholz U, Nichol G; Cancer Vaccine Clinical Trial Working Group. J Immunother 2007; 30: 1-15. Review.

Publications prior to 2010 are credited to the Cancer Vaccine Consortium, the former name of the Cancer Immunotherapy Consortium.

 

A browser plugin may be required for the PDF file found this page.